Page 204 - 2021_06-Haematologica-web

L. Thurner et al. References
1. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 2003;44(Suppl 3):S41-47.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lym- phoma identified by gene expression profil- ing. Nature. 2000;403(6769):503-511.
3. Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;5;171(2):481-494.
4. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;27;359(22):2313-2323.
5. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;12;378(15):1396-1407.
6.Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690.
7. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463 (7277):88-92.
8. Young RM, Wu T, Schmitz R, et al. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proc Natl Acad Sci U S A. 2015;112(44):13447- 13454.
9. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary cen- tral nervous system lymphoma. Acta Neuropathol. 2011;122(6):791-792.
10. Montesinos-Rongen M, Schafer E, Siebert R, Deckert M. Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lym- phoma. Acta Neuropathol. 2012;124(6): 905-906.
11. Thurner L, Preuss K-D, Bewarder M, et al. Hyper N-glycosylated SAMD14 and neura- bin-I as driver CNS autoantigens of PCNSL. Blood. 2018;132(26):2744-2753.
12.Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest. 2005;115(5):1352-1360.
13. Preuss KD, Pfreundschuh M, Ahlgrimm M, et al. A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. Int J Cancer. 2009;125(3):656- 661.
14. Thurner L, Müller A, Cérutti M, et al. Wegener’s granuloma harbors B lympho- cytes with specificities against a proinflam- matory transmembrane protein and a tetraspanin. J Autoimmun. 2011;36(1):87- 90.
15. Preuss KD, Pfreundschuh M, Fadle N, Regitz E, Kubuschok B. Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor. J Clin Invest. 2015;125(1):316-323.
16. Merbl Y, Kirschner MW. Large-scale detec- tion of ubiquitination substrates using cell extracts and protein microarrays. Proc Natl Acad Sci U S A. 2009;106(8):2543-2548.
17. Bornkamm GW, Berens C, Kuklik-Roos C, et al. Stringent doxycycline-dependent con- trol of gene activities using an episomal one-vector system. Nucleic Acids Res. 2005;33(16):1-11.
18. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal anti- body auristatin conjugates for cancer thera- py. Nat Biotech. 2003;21(7):778-784.
19. Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP. Combination of the anti-CD30-auristatin-E antibody-drug con- jugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol. 2008;142(1):69- 73.
20. Nachreiner T, Kampmeier F, Thepen T, Fischer R, Barth S, Stocker M. Depletion of autoreactive B-lymphocytes by a recombi- nant myelin oligodendrocyte glycoprotein- based immunotoxin. J Neuroimmunol. 2008;195(1-2):28-35.
21. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classifica- tion of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
22. Gruber JJ, Olejniczak SH, Yong J, LaRocca G, Dreyfuss G, Thompson CB. Ars2 pro- motes proper replication-dependent his- tone mRNA 3’ end formation. Mol Cell. 2012;45(1):87-98.
23. Sabin LR, Zhou R, Gruber JJ, et al. Ars2 reg- ulates both miRNA- and siRNA- dependent silencing and suppresses RNA virus infec- tion in Drosophila. Cell. 2009;138(2):340- 351.
24.Gruber JJ, Zatechka DS, Sabin LR, et al. Ars2 links the nuclear cap-binding complex to RNA interference and cell proliferation. Cell. 2009;138(2):328-339.
25. He Q, Huang Y, Cai L, Zhang S, Zhang C. Expression and prognostic value of Ars2 in hepatocellular carcinoma. Int J Clin Oncol. 2014;19(5):880-888.
26. Cui L, Gao C, Zhang RD, et al. Low expres- sions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 proto- col. Leuk Res. 2015;39(2):115-123.
27. Grass S, Preuss KD, Pfreundschuh M. Autosomal-dominant inheritance of hyper- phosphorylated paratarg-7. Lancet Oncol. 2010;11(1):12.
28. Neumann F, Pfreundschuh M, Preuss KD, et al. CD4(+) T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenstrom’s macroglobulinemia. Int J Cancer. 2015;137(5):1076-1084.
29. Arentz-Hansen H, Korner R, Molberg O, et al. The intestinal T cell response to alpha- gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med. 2000; 191(4):603-612.
30. Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB. T- cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature. 1986;324(6094):258-260.
31.Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibod- ies. J Clin Invest. 1998;101(1):273-281.
32. van Venrooij WJ, Pruijn GJ. Citrullination: a small change for a protein with great conse- quences for rheumatoid arthritis. Arthritis Res. 2000;2(4):249-251.
33. Neugebauer KM, Merrill JT, Wener MH, Lahita RG, Roth MB. SR proteins are autoantigens in patients with systemic
lupus erythematosus. Importance of phos- phoepitopes. Arthritis Rheum. 2000;43(8): 1768-1778.
34. Utz PJ, Hottelet M, Schur PH, Anderson P. Proteins phosphorylated during stress- induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med. 1997;185(5):843-854.
35.Thurner L, Preuss KD, Fadle N, et al. Progranulin antibodies in autoimmune dis- eases. J Autoimmun. 2013;42:29-38.
36. Thurner L, Fadle N, Regitz E, et al. The molecular basis for development of proin- flammatory autoantibodies to progranulin. J Autoimmun. 2015;61:17-28.
37. Cappello P, Tomaino B, Chiarle R, et al. An integrated humoral and cellular response is elicited in pancreatic cancer by α-enolase, a novel pancreatic ductal adenocarcinoma- associated antigen. Int J Cancer 2009;125 (3):639–648.
38. Tomaino B, Cappello P, Capello M, et al. Circulating autoantibodies to phosphory- lated α-enolase are a hallmark of pancreatic cancer. J Proteome Res. 2011;10(1):105-112.
39.Zhou W, Capello M, Fredolini C, et al. Mass spectrometry analysis of the post- translational modifications of alpha-eno- lase from pancreatic ductal adenocarcino- ma cells. J Proteome Res. 2010;9(6):2929- 2936.
40.Grass S, Preuss KD, Wikowicz A, et al. Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for mono- clonal gammopathy of undetermined sig- nificance of the IgM type and Waldenstrom macroglobulinemia. Blood. 2011;117(10): 2918-2923.
41. Preuss KD, Pfreundschuh M, Fadle N, et al. Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactiva- tion of PP2A. Blood. 2011;118(12):3340- 3346.
42.Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470 (7332):115-121.
43. Gordon MS, Kanegai CM, Doerr JR, Wall R. Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Igα, CD79a). Proc Natl Acad Sci U S A. 2003;100(7):4126-4131.
44. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregu- lation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717- 721.
45. Mondello P, Brea EJ, De Stanchina E, et al. Panobinostat acts synergistically with ibru- tinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. JCI Insight. 2017;2(6):e90196.
46. Torchia J, Weiskopf K, Levy R. Targeting lymphoma with precision using semisyn- thetic anti-idiotype peptibodies. Proc Natl Acad Sci U S A. 2016;113(19):5376-5381.
47. Bewarder M, Preuss KD, Fadle N, Regitz E, Thurner L, Pfreundschuh M. CD3/Bars: a novel bispecific format for the treatment of B-cell lymphomas. Blood. 2016;128(22): 3516.
48. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti- CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549.
2232
haematologica | 2021; 106(8)